Votrient Pazopanib For Soft Tissue Sarcoma Approved By FDA
Votrient (pazopanib) has been approved by the FDA for the treatment of soft tissue sarcoma in patients who have already received chemotherapy. Soft tissue sarcoma is a type of cancer that starts in the fibrous tissue blood vessels, fat, muscle, or other supporting tissue in the body. The cancer develops in the mesenchymal cells. Votrient stops blood vessels that feed the tumor from growing and surviving - it stops angiogenesis. Soft tissue sarcoma is a rare cancer which has several subtypes. In the USA, approximately 10, 000 people are diagnosed with soft tissue sarcoma annually.
Tobacco Exposure And Genetics Linked To Lung Cancer Risk
According to a study in the April 25 issue of the Journal of the National Cancer Institute, genotype rs1051730-rs16969968 and objective measures of tobacco exposure are associated with each other. The link indicates that the risk of developing lung cancer is mostly, if not completely, caused by the level of tobacco exposure. Scientists are aware of the link between the rs1051730-rs16969968 genotype and heaviness of smoking, an individual's risk of lung cancer and other smoking-related outcomes.
Common Environmental Contaminant Linked To Rapid Breast Cancer Growth
Studies by researchers at Dominican University of California show that breast cancer cells become increasingly aggressive the longer they are exposed to small concentrations of cadmium, a heavy metal commonly found in cosmetics, food, water and air particles. The study by Maggie Louie, associate professor of biochemistry, shows exposure to cadmium for prolonged periods of time can cause the progression of breast cancer to become more aggressive. Her findings were presented at the annual meeting of the American Society for Biochemistry and Molecular Biology, held in conjunction with the Experimental Biology 2012 conference in San Diego.